A company called Wave Life Sciences got good news this week. The company is testing a new drug. The drug is for a rare sickness. After the company shared the test results, the price of its stock went up.
Wave Life Sciences is a company that makes medicine. The company trades on the stock market under the code "WVE." A stock is a small piece of a company. People can buy it or sell it. When more people want to buy a stock, its price often goes up. When more people want to sell, the price often goes down.
The drug is called WVE-006. It treats a sickness called alpha-1 antitrypsin deficiency. People call it AATD for short. AATD is a rare sickness. It runs in families. It can hurt a person's lungs and liver over time. People with AATD do not make enough of a protein. That protein protects the lungs. Their bodies also make a bad, broken form of it. The broken form can build up. It can hurt the liver.
New test results showed that WVE-006 helped patients make more of the good, protective protein. At the same time, the drug lowered the amount of the bad, broken protein in their bodies. These good changes lasted for at least three months after patients got their last dose.
The tests also found something new. During sickness or stress, the drug let the body make more of the good protein on its own. Current AATD drugs cannot do this. Patients got the drug two ways. Some got it every two weeks. Some got it once a month. Both ways worked well.
Christopher Wright is the chief medical officer at Wave. That means he is the top doctor in charge of the company's drug research. He said, "We have now seen consistent results across multiple groups that support WVE-006's potential to protect both the lungs and liver."
The company also said the drug looked safe. Side effects were mild to moderate. Doctors did not find serious safety problems or liver harm in the tests.
After this news came out, WVE stock jumped 7%. This happened in after-hours trading on Monday. After-hours trading happens after the regular stock market closes for the day. Even with this jump, the stock is still down 60% since the start of the year. Buying and selling stock is risky. Prices can go up or down for many reasons.
Many small investors post on a trading site called Stocktwits. After this news, many of them changed how they feel about WVE. Before the news, many were "bullish." That means they expected the stock to rise. After the news, many became "extremely bullish." More people also started posting about the stock online.
Wave Life Sciences plans to talk with the FDA in the middle of 2026. The FDA is the U.S. government agency that checks if new drugs are safe. It decides if drugs can be sold. Wave wants a faster path to get the drug approved. This is called accelerated approval. Wave also expects more test results later in 2026.
AATD is a rare disease. That means it does not affect many people. Drug companies often study rare diseases because there are few good treatments. A new drug that works well can help a small group of patients a lot. It can also mean a lot for the company that makes it.
Right now, WVE-006 is still in testing. It has not been approved by the FDA yet. That means people cannot buy it as medicine today. More tests and more data will decide if the drug moves forward. The talks with the FDA in mid-2026 will be a big next step.
This story reports facts about a company's drug tests and its stock price. It is not advice to buy or sell any stock. Stock prices change often. They can go up or down fast, and no one can predict them for sure.
